Oculomucocutaneous syndrome
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oculomucocutaneous syndrome is characterized by keratoconjunctivitis sicca and by scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva.[1] It is a drug side effect observed in practolol and eperisone. It is speculated that antibodies against drug metabolites cause the syndrome.[2]
References
- ↑ Wright, P (Mar 15, 1975). “Untoward effects associated with practolol administration: oculomucocutaneous syndrome”. British Medical Journal. 1 (5958): 595–8. PMC 1672788. PMID 1125623.
- ↑ Amos, HE (Feb 18, 1978). “Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome”. British Medical Journal. 1 (6110): 402–4. PMC 1602979. PMID 146533. Unknown parameter
|coauthors=ignored (help)
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH